Dr Benjamin Chan

Dr David Pride

Dr Richard Alm

Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company.  He has supported the progression of small molecule compounds from discovery through to late-stage clinical development.  He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada. Richard is also a consultant on the Global Action Plan on Antimicrobial Resistance for the World Health Organization (WHO).

Dr Dave Ousterout

Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.

Dr Joe Campbell

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group.  The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.

Dr Shawna McCallin

Dr Henry Chambers

Dr Mimi Yen

Dr Tobi Nagel

Photo Credit: Mark Warren

Phages for Global Health is a nonprofit organization that facilitates the application of phages to combat antimicrobial resistance in developing countries. We accomplish this mission in two general ways: by delivering laboratory training workshops through which we teach scientists in developing countries how to isolate and characterize phages locally; and by partnering with developing world researchers to co-develop phage products for specific applications in their countries. Before founding Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide.

Dr Frenk Smrekar

Dr Danish Malik

Dr Nick Conley

Dr. Nick Conley is Principal Scientist for Locus Biosciences.  Before joining Locus in 2018, Nick was co-founder of EpiBiome, a South San Francisco-based precision microbiome engineering company that built the world’s first fully automated high-throughput phage discovery, characterization, and genomics platform, where he served in various roles, including CEO and Chief Science Officer.  During this time, the company gained admission into Illumina Accelerator, Johnson & Johnson Innovation’s JLABS, and Stanford-StartX; secured non-dilutive funding from the Bill & Melinda Gates Foundation and the US Department of Defense; established a top-3 pharma partnership; and raised more than $10 million dollars in financing.  Prior to EpiBiome, Nick was Staff Scientist at HGST, a Western Digital Company.  Nick completed a postdoc in Developmental Biology at Stanford University, and he holds a PhD and BS in Chemistry from Stanford University and The University of Texas at Austin, respectively.

Dr Sailaja Puttagunta

Dr Graham Hatfull

Dr Bob Blasdel

Greg Merril

Professor Martha Clokie

Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens. Her work encompasses all aspects of phage therapy development – from unravelling fundamental biology to product development, and commercialisation.  She is currently developing phages for major gut pathogens including Clostridial and Salmonella species, for respiratory pathogens and for antibiotic resistant bacteria that cause UTIs.  She is also developing a phage based diagnostic test for Borrelia. Three patents have been filed from her work.